Biotech Startups

Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.

4 investors

Allay Therapeutics develops localized pain management technology designed to deliver several weeks of post-surgical pain relief. The company focuses on supporting patients through recovery following surgery.

4 investors

Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches. The company aims to expand CAR T treatment access through scalable manufacturing, lower costs, and faster treatment delivery.

4 investors

Alloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.

4 investors

Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.

4 investors

Develops therapeutics targeting altered NAD metabolism in cancer, using IP licensed from Yale University. Based in New Haven, CT.

4 investors

Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic. It focuses on hard-to-drug cancer targets such as mutant KRAS and mutant AKT E17K across malignancies including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancers.

4 investors

Altis Labs provides tools for analyzing medical imaging data to help biopharma sponsors gain insight during drug development, and supports clinicians and scientists conducting medical imaging research. The company serves the biopharmaceutical and clinical research market in the medical imaging space.

4 investors

Alveo Technologies makes a palm-sized molecular diagnostic analyzer with preloaded test cartridges that deliver on-site pathogen results in under an hour, with results sent to a smartphone. It targets point-of-need infectious disease detection, including avian influenza testing for poultry farms and workers.

4 investors

ALX Oncology is a clinical-stage biopharmaceutical company developing cancer therapies, including its lead candidate evorpacept for immuno-oncology and ALX2004, an antibody-drug conjugate targeting EGFR-positive tumors. Its work focuses on novel treatments intended to extend the lives of cancer patients.

4 investors

Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.

4 investors

AminoChain builds decentralized infrastructure for biomedical research that connects biospecimens, participant consent, and research data through a network of biorepositories. The platform provides AI-powered search for biospecimens and participant management systems for prospective research studies.

4 investors

Developing broad-spectrum antifungal agents for invasive fungal infections. (Acquired by Pfizer)

4 investors

Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells. The company is a late-stage preclinical biotech focused on precision biologics for immune-mediated disease.

4 investors

Animab is a biotechnology company developing oral antibody-based products that target intestinal pathogens to improve gut health in livestock, with a focus on protecting piglets during the post-weaning stage. Its technology integrates antibodies directly into animal feed to prevent bacterial colonization, reducing infections and antimicrobial use.

4 investors

Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases. The company combines proprietary chemistry, target biology, and predictive sciences to advance drug candidates for cancer and other therapeutic areas.

4 investors

Antarka develops a skin-permeable enzyme derived from Antarctic organisms that repairs UV-induced DNA damage, offered as a high-purity active ingredient for cosmetic brands to formulate into anti-aging creams, sunscreens, and repair serums. The company operates in the biotech and dermocosmetics space, supplying formulators rather than selling finished consumer products directly.

4 investors

Antheia uses a yeast-based biosynthesis and fermentation platform to manufacture Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) for essential medicines, offering an alternative to fragile agricultural sourcing. The company targets pharmaceutical supply chains, aiming to reduce drug shortages and improve reliability for medicines traditionally derived from plants.

4 investors

Anthrogen develops Odyssey, a family of protein language models with 102 billion parameters designed for multi-objective protein design. The models provide an API for researchers and organizations in biotechnology and drug discovery.

4 investors

Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program. Its treatments aim to suppress HBV replication and work toward a functional cure for HBV-infected patients.

4 investors

Applied Cognition develops neuroscience-based therapeutics and diagnostics, leveraging AI and deep expertise in drug development and clinical research for neurological disorders. The company combines scientific discovery with translational research and commercialization capabilities.

4 investors

Apreo Health develops a bronchoscopic treatment for severe emphysema using a self-expanding airway scaffold designed to reduce trapped air and improve lung function. The company targets patients with severe emphysema who have limited treatment options.

4 investors

Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches. The company is developing a portfolio of DNA editing technologies capable of targeting over 90% of the human genome for therapeutic applications.

4 investors

4 investors